Article

May 15, 2004

Allergy agents popular with both physicians and patients

Rapid relief, good safety profile, long-term efficacy are advantages for highly effective drugs

Related Videos

J. Peter Campbell, MD, MPH

Expanding accessibility of vision correction with spectacles for children with cranial abnormalities

Elkin: Talking about the importance of pediatric eye health and safety

Identifying 3 barriers keeping families from accessing cataract treatment for their children in India

Edward Manche, MD

Related Content

NIH highlights 5 key elements of cortical visual impairment (CVI)

November 23rd 2024

NIH highlights 5 key elements of cortical visual impairment (CVI)

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Cerebral visual impairment is a growing concern in pediatric vision loss

November 14th 2024

Cerebral visual impairment is a growing concern in pediatric vision loss

Managing a changing landscape of IRD pediatric cases

May 10th 2021

Managing a changing landscape of IRD pediatric cases

FDA grants fast track status to FELIQS’ FLQ-101 for ROP

November 6th 2024

FDA grants fast track status to FELIQS’ FLQ-101 for ROP

Cerebral visual impairment: A growing concern in pediatric vision loss

October 30th 2024

Cerebral visual impairment: A growing concern in pediatric vision loss

Related Content

NIH highlights 5 key elements of cortical visual impairment (CVI)

November 23rd 2024

NIH highlights 5 key elements of cortical visual impairment (CVI)

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Cerebral visual impairment is a growing concern in pediatric vision loss

November 14th 2024

Cerebral visual impairment is a growing concern in pediatric vision loss

Managing a changing landscape of IRD pediatric cases

May 10th 2021

Managing a changing landscape of IRD pediatric cases

FDA grants fast track status to FELIQS’ FLQ-101 for ROP

November 6th 2024

FDA grants fast track status to FELIQS’ FLQ-101 for ROP

Cerebral visual impairment: A growing concern in pediatric vision loss

October 30th 2024

Cerebral visual impairment: A growing concern in pediatric vision loss

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.